Recombinant human thymosin beta4 - Beijing Northland Biotech
Alternative Names: NL-005; Recombinant human thymosin β4 - Beijing Northland BiotechLatest Information Update: 14 Aug 2023
At a glance
- Originator Beijing Northland Biotech
- Class Anti-ischaemics; Recombinant proteins
- Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Collagen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myocardial infarction
Most Recent Events
- 29 May 2023 Beijing Northland Biotech completes a phase II trial in Myocardial infarction (In adults, In the elderly) in China (IV) (NCT05984134)
- 18 Nov 2021 Beijing Northland Biotech completes a phase II trial in Myocardial infarction (In adults, In the elderly) in China (IV) (NCT05485818)
- 23 Nov 2020 Phase-II clinical trials in Myocardial infarction (In adults, In the elderly) in China (IV) (NCT05485818)